Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Hypogammaglobulinemia

Hypogammaglobulinemia

0 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Hypogammaglobulinemia

6 trials tracked for Hypogammaglobulinemia: 3 in phase 3 or 4 and 1 with published results. The most-cited published study has 42 citations.

6Trials tracked
3Phase 3 & 4
0Recruiting
1With published results
Phase distribution
Phase 3 3 Phase 2 2 Other / NA 1
  1. Phase 3 Plerixafor Versus G-CSF in the Treatment of People With WHIM Syndrome Completed · 42 cited
  2. Phase 3 Efficacy and Safety Study of Kedrion IVIG 10% to Treat Subjects With Primary Immunodeficiency (PID) Completed
  3. Phase 3 Efficacy, Safety and Pharmacokinetics of Gammaplex in Primary Immunodeficiency Diseases. Completed
  4. Phase 2 Intravenous Immunoglobulin (IVIG) in Lung Transplantation Completed
  5. Phase 2 Lenalidomide and Ofatumumab in Treating Participants With Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Completed
  6. N/A Post-bypass Prophylactic IVIG in Infants and Neonates Completed

Showing the 6 most-cited and recently-updated of 6 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found For clinicians

Hypogammaglobulinemia: what the trials found

Intravenous immunoglobulin (IVIG) has been evaluated in patients with primary immunodeficiency diseases, demonstrating a significant reduction in the number of serious, acute, bacterial infections (SABIs) per subject per year to zero (p=0.01) 3.

Clinical assessments of IVIG therapy also showed no statistically significant difference in post-operative infection rates or bloodstream infections among study groups 6. Additionally, data on IVIG administration was collected in a Phase 2 trial setting 5.

Treatment with Kedrion IVIG 10% was associated with specific metrics regarding morbidity from infection, including 2.8 days out of work/school/daycare and 3.4 days unable to perform normal daily activities 2.

Plerixafor did not demonstrate a statistically significant difference in the Total Infection Severity Score (p=0.65) 1.

Recent results — preliminary, needs further review

  • Lenalidomide was evaluated in a Phase 2 trial for this condition, but results are not yet corroborated 4.

For the clinician treating this condition

  • IVIG is associated with a significant reduction in the annual incidence of serious, acute, bacterial infections (SABIs) in patients with primary immunodeficiency 3.
  • While IVIG is used for management, clinical data shows no statistically significant difference in post-operative infection or bloodstream infection rates compared to other groups in specific study cohorts 6.
  • Plerixafor did not show a statistically significant impact on the Total Infection Severity Score 1.

AI synthesis of 6 cited trials, updated Aug 14, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
No published articles yet for this condition. Check back soon.